(Q37623112)

21 August 2017

1 reference

title

Emerging inflammatory markers for assessing coronary heart disease risk (English)

1 reference

21 August 2017

0 references

1 reference

coronary artery disease

1 reference

Marshall A Corson

1

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Current cardiology reports

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

452-459

1 reference

Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes

21 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-009-0065-1

Use of biomarkers to develop treatment strategies for atherosclerosis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11886-009-0065-1

Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16

21 January 2018

1 reference

12 December 2020

Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2

1 reference

12 December 2020

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial

1 reference

12 December 2020

Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors

1 reference

12 December 2020

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

1 reference

12 December 2020

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study

1 reference

12 December 2020

Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study

1 reference

12 December 2020

Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update

1 reference

12 December 2020

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

1 reference

12 December 2020

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

1 reference

12 December 2020

HDL, lipid peroxidation, and atherosclerosis

1 reference

12 December 2020

B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department.

1 reference

12 December 2020

Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study

1 reference

12 December 2020

Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans

1 reference

12 December 2020

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

1 reference

12 December 2020

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

12 December 2020

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

1 reference

12 December 2020

Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.

1 reference

12 December 2020

Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia

1 reference

12 December 2020

The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines

1 reference

12 December 2020

C-reactive protein and coronary heart disease: a critical review

1 reference

12 December 2020

Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction

1 reference

12 December 2020

Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk

1 reference

12 December 2020

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

1 reference

12 December 2020

Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age

1 reference

12 December 2020

Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence

1 reference

12 December 2020

Role of secretory phospholipases in atherogenesis

1 reference

12 December 2020

Myeloperoxidase, modified lipoproteins, and atherogenesis

1 reference

12 December 2020

B-type natriuretic peptide (BNP) and proBNP: role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders

1 reference

12 December 2020

Variability of lipoprotein-associated phospholipase A2 measurements

1 reference

12 December 2020

Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastat

1 reference

12 December 2020

Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein

1 reference

12 December 2020

Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations

1 reference

12 December 2020

Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites.

1 reference

12 December 2020

Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques

1 reference

12 December 2020

Genetically elevated C-reactive protein and ischemic vascular disease

1 reference

12 December 2020

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker

1 reference

12 December 2020

Interleukin-18 and the risk of future cardiovascular disease among initially healthy women

1 reference

12 December 2020

Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome

1 reference

12 December 2020

Biomarkers of atherosclerotic plaque instability and rupture

1 reference

12 December 2020

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

1 reference

12 December 2020

Determination of myeloperoxidase in EDTA plasma: comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

CD40/CD40L system and vascular disease.

1 reference

12 December 2020

10.1007/S11886-009-0065-1

Identifiers

DOI

1 reference

21 August 2017

1 reference